Background Malignant pleural effusion (MPE) is a common problem for people with cancer
and usually associated with considerable breathlessness. A number of treatment options are …

With no cure for malignant pleural effusion, efforts are focused on symptomatic
management. Historically, this symptomatic management was achieved with the instillation …

Background The prevalence of malignant pleural effusion is increasing worldwide, but
prognostic biomarkers to plan treatment and to understand the underlying mechanisms of …

Background Pleurodesis is done as an in-patient procedure to control symptomatic recurrent
malignant pleural effusion (MPE) and has a success rate of 75–80%. Thoracic …

Physician-led thoracic ultrasound (TUS) has substantially changed how respiratory
disorders, and in particular pleural diseases, are managed. The use of TUS as a point-of …

Background and objective Non‐expansile lung (NEL) frequently complicates management
of malignant pleural effusion (MPE) and is an important factor in clinical practice and trials …

Pleural disease diagnostics represent a sprawling topic that has enjoyed a renaissance in
recent years from humble beginnings. Whilst pleural patients are heterogeneous as a …

Symptomatic pleural disease, specifically malignant pleural effusion, refractory benign
pleural effusion, and pneumothoraces are common diseases that often require therapeutic …

Background and objective IPC in patients with MPE are removed within 3 months in 30–58%
of cases, usually due to decreased pleural fluid output as a result of pleurodesis. Disease …

Pleural effusion is a common condition, affecting over 3,000 people per million population
every year. More than 50 causes of pleural effusions are known, including pleural infection …